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Gout has been recognized since antiquity as a clinical 
disease. It Has originally ca.lled !lodagra from the Greek pous, 
foot and agra meaning attack. The term gout is derived from 
the Latin, gutta meaning drop.23 Stedman's Eedical Dictionary 
defines gout as tla disease of metabolism characterized by recurrent 
attacks of arthritis, particularly in the metatarsophalangeal joint 
of the great toe, though any joint may be attacked, by depOSits 
of sodiu..1!l biurate in and around the affected joints, and by 
inflammation of fibrous structures els~ihere. 11_21 The term gout may 
also be used to describe acute or chronic gouty arthritis or chronic 
deforming gouty arthritis. 
¥.J.storically gout has been a1luded to in many ancient "r.ri tings. 
For example, ,,,,e find in the Old Testament in 2 Chronicles, chapter 
16, verse 12, "In the thirty-ninth year of his reign Asa was 
diseased· :Lr: his feet, and his disease became severe; yet even in 
his disease he did not seek the Lord, but sought he~p from 
physicians. ul2 It is certainly highly probable that the disease 
referred to in th=~s passage of Scripture was gout, e.nd this l"'aS 
wri t ten before the founde.tion of the :a.oman empire! Hippocrates, 
460-370 B.C., knew gout as the umlalkable disease • .ll Likewise, many 
famous persons in history have had or are thought to have had gout. 
A,'Uong these are: Achilles, Oedipus, Henry VII, Hartin ruther, 
Henry VIII, John 'hi'esley, John Calvin, Francis Bacon, Oliver 
1 
Cromwell, Alexander the Great, Benjamin Fr£illklin, Louis XIV, 
Goethe, New-ton and Charles Dandn.23 It has been estimated that 
approximately 800, 000 persons hl the United States alone suffer 
from gout so it is not a rar-e condi t-Lon. }I HOvT many of those ,,;:ho 
suffer vIi. th gouty arthritis which is undiagnosed and untreated is 
anybody's guess. Since gout is one of the only types of arthritic 
condition whj_ch can be successfully treated it is indeed a pity that 
anyone should suffer from this disease. 
EPID111UOLOGY 
As mentioned above there are approximately 800,000 gout 
sufferers in the United States alone not to mention the untold 
thousands throughout the rest of the world. 9 The incidence of gout 
can only be estimat-ed hOvIever, so there is a large divergence of 
opinion regarding the actual incidence. At ~ny rate it is a fairly 
prevalent disease and one~lhich causes almost intolerable pp.J.n in 
severe cases. Sidney Smith, an eighteenth-century clergyman, wrote, 
f'1men I have gout I feel 2,8 if I were walking on ill,! eyeballs. 11,5 
Gout has by far its greatest incidence in the male. It is 
generally agreed that the sex incidence is 95.5% medes 2nd j.+.5% 
females. 5.,1?.:,~;3 No good explenation ha:3 been given for this aberr;mt 
sex ratio but a number of possibilities have been suggested. It is 
thought that the ratio may be attributed to the hereditary trans-
mission of gout. It has also been hypothesized that it may be due 
to a low fertility rate among married women 1II.rith gout. 23 It has also 
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been suggested tha.t 1rIOmen can tolerate a higher uric acid level ",'ith-
out showing the overt clinical manifestations of gout. vmatever the 
Cfmse the sex r2tio of 95.5/L5 has been well documented clinicp~ly. 
The average age of onset of clinical manifestations of gout is 
about 115, but the first attack may occur as early as the first decade 
of 1ife.5,23 Other individuals may not have clinical gout until the 
3th or 9th decade of life. It is highly probable that individu.?~s 
"mo do not develop clinical gout until late ir life have haJ a high 
serum uric acid for mp.ny years but for some reason have not 
develoned the manifestations until late. 
The race distribution of gout has not been well documented. 
Gout has been described in all parts of the world. It has been 
previously assumed that Ni3groes 111ere more or less free of the 
disea.se, but as better methods of diagnosis are found and more 
interest is generated in gout it is being reported vuth greater 
frequency in Negroes. 2J 
A sea.sonal incidence of acute attacks of gout has been des-
cribed. It haB been reported that attacks occur 1l1..Qst corn:monly in 
early spring and late fall. 2~9 This seems to correspond ~lith 
appa.rent changes in other t;}rpefo of arthritic em.d rheum3tic condi t-
ions which occur during changes in barometric pressure ?.nd which 
allo1rl'S the rheumatism sufferer to predict changes in the l"eather. 
It haC" been f01"'t~.erly thought that gout was due to over indul-
gence in alcohol or food '~an'd . that theref'ore .. i t:.was a dise.ase of 
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wealthy persons rather than the poor. However, 1\fe nov] know that 
gout is an hereditary disease and thus it attacks rich and poor 
alike. 23 
ETIOIDGY 
Gout is one of a gro-vling number of diseases resulting from 
Q 
a so-called "inborn error of metabolismll ." That gout was associated 
with uric acid has been knmm for many years. Uric acid is a 
normally occUl~ring product of metabolism. Persons v.dth gout 
apparently produce an excess of this substance al':: evidenced by the 
fact that some gout patients have been shOlm to excrete excessive 
amounts of uric 8.cid 'ltJhile on a low purine diet. Thus the uric acid 
concentration in the serum of gout natients is probably a result 
of overproduction rather than inability to excrete uric acid. 
Hm-leyer, a number of other nossible causes for increased uric acid 
levels are believed to contribute to this condition. For example, 
decreased destruction of enzymes. It has been thought that a 
decreased destruction of the enzyme uricase was a possible factor 
in the occurrence of goutJ',1t,,23 However, it is knovill that allan-
to in is the degradation product of uric c.cid in lower animals so 
uricase in man should result in this same end product. Nongouty 
hump.ns, however, excrete only very small amounts of this substance 
daily so it hardly seems likely that a deficiency of uricase could 
result in full-blmm gout. ?3) 
Another popu12T theory of the etiology of gout centers eround 
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a diminished excretion of urates b~, the kic'Iney. Here again is a 
theorJ that does not stand UP under close scrutiny. If a high 
urate concentration in the sel~l is due to poor excretion by the 
kidney then other substances excreted by the kidney should also 
be improperly excreted. This is not found to be the case. Gout 
patients frequently e:{hibit no other abnormal functions. Also, 
studies evaluating the renal excretion of urates reveal little or 
no difference between gout patients and nongouty persons. 2J If 
renal impairment produced elevated uric acid levels and subsequent 
gout then we would expect patients vlith glomerular damage to 
exhibit elevated urate concentrations if not clinical gout. This, 
of course, has not been found to be the case. 
The most satisfactory explanation for the metabolic deficiency 
producing gout is that there is 2n increase in uric acid forma.tion 
resulting in an increase in the metabolic pool.2(3 This explana.tion 
would be consistent .dth the increased excretion of urates freq-
uently noted in gout patients. 
URIC ACID I'mTABOLI8M 
Uric acid is the end product of purine metabolism in man, 
but in the sub-primate ma1llillals the uric acid is further oxidized to 
al18ntoin by the action of uricase. Thus in such ani..rllals the 
principal end product of purine metabolism is allan to in instead of 
uric acid.:z. In humans urea is the end-product of nitrogenous 
substances such 8$ those of amino acid and pyrimidin origin. In 
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birds and reptiles uric acid is synthesized, and thus corresponds 
in its function to urea in man. Uric acid is apparently excreted 
in humans in almost constant a.'11ounts. Dietary intak~ except for 
purine and nucleic acid substances,does not effect uric acid 
excretion to any great extent. The purine ring is made up of 8 
nu,>nber of constituents including glycine, which fUrnishef' carbon 
atoms 4 e~d 5, carbon dioxide fUrnishing carbon atom 6, nitrogen 
8.t0!11 7, and atoms 2 and 8 are supplied by formate. The other 
nitrogen atoms come from glutamine and aspartic acid.21 
The metabolism of uric acid in man hac' been studied most 
extensively by the use of isotopically labeled uric acid. This is 
accomnlished by N15 in carbon atoms 1 and 3. Single doses of the 
labeled uric acid were injected intravenously into a normal hUi'nan 
'7 
subject and into patients suffering from gout. L The dilution of the 
injected labeled compound was used to calculate the quantity of 
uric acid 1\l'hich is present in the body water. This quantity is 
called the !fmiscible poolll. In normal subjects the miscible pool 
contains an. average of about 1130 mg. of uric acid. In subjects w-ith 
gout, the miscible pool was much larger. In a mild case of gout 
... -ith a serum uric acid of 6.9 rug./IOO ml. and no S;Yll1ptoT~lS the 
miscible pool contains about 4740 mg. of uric acid and ranges up 
to 31,000 mg. in patients with severe symptomsJ 
It is possible to estimate the "turn-overu of uric acid from 
the rate at which the N15 declines in the uric acid and this is the 
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rate at which uric acid is s;ynthesized and lost from the body. It 
has been found that the uric acid formed in the normal subject is 
from 500-580 mg. per d2_Y. Due to the fact that the quantities of 
uric acid entering the miscible pool are ~Teater than those lost 
by the urin2ry route it was found that some of the uric acid is 
not excreted but is broken dOvID chemically. Some of this uric 
acid is excreted in the bile. Imother portion,hov.1'6ver, is degraded 
to other nitrogenous products.'l 
Uric acid is only slightly soluble and tends to precipitate in 
acid urine upon standing. This factor is probably responsible for 
F'ig. 1. Pathways of Purine !1etabolism in the Human Body 
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CLINICAL DESCRIPTION 
The first sign of gout is usually an acute attack of arthritis 
in one or more of the joints of the extremities, and the diagnosis 
of gout is usually not suspected until after this first attack 
of arthritis. It is generally felt that a diagnosis should not be 
made until after this event. other prodromal signs include such 
things as elevated blood pressure, albuminuria, and renal stones. 2Di 
These la.tter findings may also remain manifestefter the initial 
episode of erticular distress. 
The initial joint distress may appear at any time of the day 
or night 8n:j at any tirEe of the year. The onset is sudden and 
usually involves the metatarsal-phalangeal joint of the great toe of 
either or both feet. The pain of any attack of gout including the 
first enisode is often so severe as to be completely incapaci-
tating.5,9,23 It is generally held that the severe 9ain of gout is 
due to effusion into the joint cavity and by edema of the surrounding 
tissues. Severel joints may be involved simultaneously during an 
acute attack, or several joints may be involved successively as in 
migratory polyarthritis of rheumatic fever. A gout infected joint 
may also be confused 1>.D-th a septic process in that the cardinal signs 
of inflalmnation ere present. 23, This inflammation often extends 
beyond the affected joint to involve the lymphatics as in a 
cellulitis. It is apparent thpt one must differentiate between a 
septic joint and 8. gouty joint so that incision end drainage will 
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not be attempted on a gouty joint or neglected on a septic one. In 
a gouty joint the skin is tense and shiny, and the color is better 
described as a cyanotic purple than a fiery red.;),23 This is not 
always the case, however, and it should be pointed out that acute 
gouty joint involvement may occasionally be indistinguishable 
clinically from joint sepsis. The systemic reaction to acute gout 
may be even more difficult to distinguish from sepsis. The acute 
attack of gout may be accompanied by fever, chills, anorexia, 
headache, and a general feeling of malaise. other points in the 
clinical picture to look for include the exquisite tenderness of 
the involved joint, engorgement of the veins in the region, and 
edema ~mich may extend well beyond the limits of the involved joint. 
Another characteristic sign of gouty arthritis occurs after about 
a week and is found in none of the other arthritides. This is the 
desquamation of the skin over the affected joint, and may resemble 
cellulitis in its appearance. 2J 
The diagnosis of gout although fairly easy to make is frequently 
rr.issed because the clinician fails to consider gout when a patient 
has an acutely inflamed joint. Also, many clinicians look upon 
gout as primarily a European disease occurring predominantly in 
persons ~mo drink excessive amomnts of beer.~ Excessive indulgence 
in either food or drink as a cause of gout has not been born out 
clinically although such overindulgence has been implicated in 
precipitating an acute attack in persons who suffer from gout..5,19,.fQ 
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A number of other substances or factors are likewise suspected in 
precipitating acute attacks. These include drugs, sex, trauma, 
blood loss, acute infections, prolonged bed rest, and surgical 
procedures. '23 
Drugs which have been implicated as inciting agents include 
vitamin B12, insulin, diuretics, thiamine chloride, ergotamine 
tartrate, and penicillin. 23 The fact that penicillin has been shown 
to precipitate attacks of gout and to aggravate the condition when 
it exists is ~;mother good reason for making a reasonable effort 
to differentiate between gout and sepsis in a case of an acutely 
inflammed joint. However, the fact that a specific drug has 
been implicated as an inciting agent in gout should never prevent 
a physician from using that drug when indicated by other pre-existing 
or concomitant conditions. Such drugs should not be used w"ithout 
careful consideration ho~~ver. 
Direct trauma as a precipitating c>gent in gout me~ be readily 
explained by the f2ct that there is frequently urate deposition in 
persons subject to gout and a blow to such an area could more 
easily produce acute inflammation. Persons vuth gout should be 
especially ce~eful to have properly fitted shoes because ill-fitting 
shoes could easily provide sufficient trauma to precipitate an 
attack of gout. 
The most important feature in the early diagnosis of gout and 
gouty arthritis if' the history.5 First of all a family history of 
gout should immediately alert the attending physician to the 
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possibility of gout as the diagnosis. Like\~d.se, the history of 
the onset of the acute attack should lead to the correct diagnosis. 
Chcracteristic of an acute attack of gout is the speed of onset. 
A typical story ffiRY be that the patient goes to bed feeling 
perfectly iiell and awakens a few hours later v..D. th excruciating pain 
and swelling usually in the great toe of either foot.5 The severity 
of the pein is another differentiating point in making the diagnosis 
of gout. The pain may be so severe that even the Yl3ight of bedding 
is intolerable. 'The duration of the first attack also aids in 
mru<ing the diagnosis of gout. The usual duration of the first 
attack is from five days to about ten days or two \veeks.5 T'ne 
s;;nnptoms usually disappear rather suddenly leaving the patient • .nth 
no residual contplaints. Another notable characteristic of gout 
is the periodicity of the attacks which usually occur every six 
months to year and 8 half. The attacks gradually become H:ore 
frequent and a more chronic phase is reached, usually after about 
two decades, in which the pain and discomfort may be almost con-
stant. This is usually knm.'I1 as the chronic tophacious phase. 
Between the acute attacks in patients without joilnt deforrr..ities 
there a:e no overt signs or sympto:ns. '1'hese periods of quiescence 
in the course of gout are known as the intercritical periods. 20 
The tophi, which are used by all too many clinicians as 
diagnostic criteria, but which usually do not appear until well 
after the diagnosis should h:?Ve been made, are the result of urate 
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deposition in subcutaneous tissues. These urates are the salts of 
uric acid and are not usu2~ly deposited as subcutaneous tophi until 
the gout has been present for some tLme; however, tophi m~ rarely 
be present by the tiIl1e of the first attack. The classical site of 
tophi is on the ear, and these may be identified as white nodules 
on the helix in long standing C2~ses of gout. Other common si tea 
for tophi include subcutaneous tissues over joints of the hands 
and feet, the olecrrul0n bursa, the knees, and, less COID~Only, the 
buttocks.2;.3 
Another ~~portant diagnostic feature in gout is the elevation 
in the serum uric acid concentration. This elevation is invariably 
found in gout patients, but an increased concentration of uric acid 
does not always produce clinical gout. Gouty p2tients have elevated 
uric acid levels before and during acute attacks as well aEi during 
the intercritical periods ~~ess uricosuric agents are administered. 
The normal leve1 for uric acid in the serum is 2 to :5 mg./lOO mI. 
Gouty patients usually have serum uric acid levels of 6 mg./lOO ml. 
or greater. Uric Bcid levels of 10 to 12 mg./IOO ml. are not 
infrequent in gouty patients. 7,23 
Other criteria ltlhich may aid in making the initial diagnosis 
of gout include urate stones or calculi, albuminuria, hypertension, 
and increased sedimentation rates. 2,3 As a matter of fact, urate 
lithiasis and hypertension may precede the initial attack. 
In addition to laboratory diagnostic aids we would most certainly 
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wi.sh to make use of radiographic evidence.. However, it must be 
noted that gouty patients do not always exhibit abnormalities 
detectable by X-ray so roentgenographic studies may be counted on 
only for aid in the diagnosis of gout, and only in some of the pat-
ients. In any case, hO't1fever, reQiographic studies should be employed 
'n any patient suspected of having gout. 
The metatarsal-phalangeal joint of the great toe is often one 
of the first ~reas to show changes on X-ray. There is usually a 
narro1rung of the joint space with bony overgrowth at the joint 
margins. 'I'here ffi2JT also be sorr~e decrease in density of the head of 
the first metatarsal adjacent to the joint space. Soft tissue 
swelling is also usually in evidence even =_n the absence of other 
demonstrable bony changes during the acute phase of the disease. 
1bphi are exhibited on X-ray as circular or ovoid areas of decreased 
density with distinct and sharply defined margins. 23 
One other factorvlhich may be of diagnostic value is the 
response of the p2,tient to concllicine therapy.. It is generally held 
that if colchicine is used for diagnosis full therapeutic amounts 
should be given. Likewise, since colchicine therapy may interfere 
w~th results of laboratory tests for gout, any patient taking 
colchicine or any other uricosuric drug should have those drugs 
withheld for h8 hours or more before any other diagnostic laboratory 
tests a.re obtained. A favorable response to a uricosuric drug by 
a patient suspected of having gout on the basis of other factors 
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m~~es the diagnosis of gout vertually certain. 
DIF'FT~EL~NTIAL DIAGNOSIS 
Since there are a nUJnber of conditions lvhich simulate gout 
and gouty 2~thritis it is necessary to be able to recognize these 
conditions and rule them out when attempting to diagnose a case of 
gout. Acute rheumatic fever and acute gouty arthritis are very 
difficult to differentiate. The age of the patient may be of some 
help in differentiating but certainly cannot be used as the sale 
factor since older -persons Y'Jay have rheumatic fever just as young 
individuals may have gouty arthritis. Articular distress is usually 
more acute in gout than in rheumatic fever. The sex incidence may 
also be of significance. A young female patient -v.rith acute arthritis 
is much more likely to have rhe'U1n2.tic fever than gout. Likelflse, 
an elderly male "ld th articular cO:1'plaints is more likely to have 
gout. Electrocardiographic changes and cardiac pY!llptoms favor a 
diagnosis of rheumatism. Other differentiating factors include 
response to colchicine and radiographic evidence. X-rays of 
rheumatic joints ShOl>l soft tissue slrelling only without evidence of 
bony changes. 
Another Significant disease which must be ruled out before 
making a diagnOSis of gouty arthri.tis is rheumatoid arthritis. 'TIle 
differential in this case should not be so difficult to make. In 
rheumatoid arthritis the joints tend to be involved symmetrically, 
and the onset is not so sudden nor the articular pain so unbearable. 
-lh-
The duration of attacks is longer for rheumatoid arthritis than 
for gout. This is not to s~ that theEe two conditions cannot occur 
concomitantly in the sa.'Tle patient, in 1ihich case the differentiation 
would be fore difficult but less necessary. Of course, the final 
diagnosis may ~w~s be readily made histologically from biopsy of 
a tophus or a synovial membrane. 
In older patients osteoarthritis, or degenerative joint 
disease, must be considered in the differential diagnosis with 
gouty arthritis.l~ The Heberden's nodes, which occur on the terminal 
interphalangeal joints, may somewhat resemble the tophi found in 
gout. It seems, however, that ioJOmen are more prone to the develop-
ment of acute Heberden's nodes; therefore, since women seldom have 
gout, the differentiation here should usually be re 1 at ive 1:'0" easy. 
IUS 0 , acute articular s:ylllptoms are rare :i_n osteoarthritis and are 
the rule in gouty arthritis. 
Septic joint involvement has been mentioned previously in the 
section on diagnosis. However, it should be mentioned again since 
the symptoms of sepsis in a joint "rill probably most closely 
resemble those of gouty arthritis. A septic joint, like a gouty 
joint, may be red, warm to the touch, swollen, and extremely tender, 
although probably not quite so exquisitely tender as a gouty joint. 
It should be again emphasized that it behooves the attending 
nhysician to attemnt to differentiate these two conditions because 
". l:.! ... 
of the fact that antibiotics may aggravate gout. 
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PIlEVENTIOlJ Al\1J) TREAT1·1ENT 
S'ince gout is generally held by authorities to be a disease 
of hereditary origin there is little in the way of prevention that 
can be done unless one is able to pick his ancestors. This, we must 
presume, lies beyond the scope of medical science, at least for the 
present. It is kno'W""!l that persons, especially males, whose parents 
or grandparents have gout are much more likely than others to have 
elevated serum uric acid levels, if not clinical gout. Most author-
ities l~~ould probably agree that relatives of known gout patients who 
have hyperuricemia ~~thout symptoms should be informed that they are 
potential gout victims. Such individuals should avoid obesity, 
excessive trauma to joints, and high purine foods. Hyperuricemic 
indiiTiduals should be identified by the physician as potential gouty 
patients so that 1men and if the initial acute attack occurs it may 
be correctly diagnosed aTJ.d the proper treatment recommended. Of 
course therapy in gouty subjects should be directed toward the 
nrevention of the chronic tophacious 11anifestations which may be 
disabling in severe cases. This can be done with proper therapy 
in a cooperative patient. 
It has been previously stated that gout is the only arthritic 
condition that C8n be effectively treated at present. Therefore, it 
is proper that considerable attention be naid to the treatment of 
gout. It should be understood at the beginning that gout cannot 
be cured. It is, h01l1ever, a chronic disease that can be effectively 
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treated to reduce the number of acute attacks and to prevent the 
chronic manifestations. It is this IItreatmentll with which we will 
concern ourselves here. 
Colchicine is one of the oldest drugs in the pharmacopeia and 
has been known for many years to be specific in the treatment of 
gout.23 The autumn crocus or Colchicum auturrlllale, the source of 
colchicine, hAS been in use since 600 A.D. according to GrahamJ' 
Ho,rever, the mechanism of the action of colchicine remains a 
mystery even today. This drug is the active prinCiple of the 
tincture of colchicum and is present in many species of plants of 
that genus. It is not an analgesic drug and 1s useless as treatment 
in other t:vpes of arthritis. Another irnportant fact is that 
colchicine is not a uricosuric agent, nor 1s it a diuretic. 
Colchicine seems to be specifically effective for regular use as 
a prophylactic agent in the gout patient, and it is especially 
helpful in relieving the symptoms of the acute attack of articular 
distress. In treating the acute 8.ttack it is recommended that 
colchicine be given in doses of 1 mg. every tV-TO hours for five 
doses the first day of the attack and in smaller doses as the 
attack diminishes. If very rapid action is necessary or desired 
colchicine may be administered intravenously in doses of 2 to 3 
mg. given slowly.5,20,23 This produces dramatic relief in about three 
hours. Because of its irritating effec~ care should be taken to 
place the colchicine directly into the vein and not into tissue. 
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As mentioned above conchic:Lne is recommended for use during 
the intercritical period between acute attacks. In this capacity 
dosages of 0.5 mg. are given three or four days each l'feek in the 
milder cases, and one tablet each day in more severe cases. 28 The 
use of colchicine has been found to be beneficial in pro1:)hylaxis 
against the acute att2.ck especially in combination \u th Benemid 
wilich will be discussed 18.ter. Colchicine is apparently well 
toler2.ted 1~nen taken over long neriods of time and sensitivity does 
not seem to develop.2'? Unfortunately the toxic and full therapeutic 
doses are very close together, and this fact is frequently used to 
determine the maximum tolerable dose for a given patient With severe 
gout.;i;O The toxic or side effects of excess colchicine intake are 
usually confined to the gastrointestinal tract. These symptoms 
include nausea, vomiting, and abdominal pain. Gastrointestinal 
upset is apparently not a factor '({hen the drug is administered intra-
venously, so this route is recommended for attacks of gout which have 
been precipitated by surgical trauma. 
Phenylbutazone (Butazolidin) is another drug which is effective 
in the treatment of gout lmen administered orally. 23 This drug has 
the advantage of being an excellent analgesic agent as well as 
having anti-inflammatory properties. Phenylbutazone should be 
started soon aSter the onset of symptoms. A large initial dose 
of 400 to 600 mg. is follolred two hours later by 260 mg. and four 
hours after that by another 200 mg., thus making a total of 800 to 
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1000 mg. for the first day. The follovring two or three days hoo 
mg. daily should be given in divided doses until symptoms have 
disappeared. The relief of symptoms "nth this drug is rapid, but 
numerous undesirable side effects may result. Among these are salt 
and water retention which may lead t.o congestive heart. failure and 
acute pulmonary edema. Nausea, vomiting, nervousness, insomnia, 
skin rashes, blurring of vision and bone marrOvJ depression have also 
been attributed t.o phenylbut.azone. 23 Thus phenylbutazone is not 
recommended for long term or prophylactic administration. 
Probenecid (Benemid) (p-(di-n-propylsu1famyl)-benzoic acid) 
was s3mthesi#ed following the observation by Wolfson and associates 
in 1948 that carinamide inhibited uric acid reabsorption. 23 Benemid 
has no analgesic or anti-inflammatory properties and is of no value 
in controlling the acute attack of gout. l~either is it a cure for 
gout. As a matter of fact, Benemid he.s been found to actually 
increase the number of acute attacks during the first few months of 
its administration. HOwever, this drug has been found to be of 
significant value in the prophylaxis of acute attacks when it :is 
used conscientiously over periods of several ~nnths to several years. 
Benemid seems to be more effective when used in combination with 
colchicine. 
Benemid, unlike colchicine, is a urate diuretic drug or, as 
it is more commonly called, a uricosuric agent. It acts by reducing 
the tubular absorption of glomerular filtered urate and is 
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associated with an increased excretion of uric acid in the urine, 
a decreased concentration of uric acid in the serum, and a decrease 
in the metabolic poo1.4,23 
Probenecid was originally developed for the specific purpose 
of inhibiting renal tubular secretion of penicillin. ?nis property 
was extremely useful in the early days of penicillin when this 
substance wac scarce and expensive. la Since penicillin is excreted 
as penicillin and is not broken dOrm or detoxified in the body it 
is obvious that an agent which would provent tubular secretion of 
this drug 1-lou1d be very useful :1.n maintaining adequate blood levels 
of the antibiotic. It was later found that probenecid 1.va8 useful 
as a uricosuric agent and it is in that capacity that th:1_s drug 
is used to a great extent. Sirota &'1d associates reported in 1952 
that Benemid. has no significant effect on glomerular filtration, 
and that tI data obtained support the complete filtration-partial 
tubular reabsorption concept of urate excretion in the normal and 
gouty subject and indicate that Benemicl uricosuria is the result 
of a highly selective i!ll1ibition of tubular reabsorption of filtered 
urate rr • 1§ 
App8xently there is some antagonism between Benemid and 
sa1icy1ates, which are uricosuric in their own right. For this 
reason it is recon~ended that these two agents not be used 
simu1taneous1y.4 There do not B'3errl to be any significant toxic 
side effects of Benemid. .Uso, mild renal dysfunction is not a 
-20-
contraindication to the use of Benelnid. 23 Patients who have ~en on 
Benemid therapy for prolonged ~eriods may even show Lmproved renal 
function as evidenced by blood urea nitrogen determinations. This 
is thought to be due to the fact that Benemid may cause gradual 
depletion of urate deposits t~ich, ~nen present in the kidney, may 
interfere 'i>"n th renal function to some degree. 
In addition to the drugs discussed above, adrenal steroids have 
been used in treatment of gout. These agents, while they may be 
helpful in treating acute symptoms, Ere not recommended for pro-
longed administration. Likewise, the saliqylates, acetylsalicylic 
acid and sodium salicylate, have long been known to be useful in 
treatment of gout. Their chief merit probably lies in their analgesic 
properties. As previously mentioned, however, there is some sort of 
antagonism between salicylates and probenecid which makes it 
inadvisable to use these two agents together. 
In general there are about four stages ot gouty disease each 
of v1hich is somevihat unique in its therapy. These stages are as 
follows: stage I, the stage of asymptomatic hyperuricemia; stage 
II, the acute attack; stage III, the intercritical periods; and 
stage IV, the stage of chronic gouty arthritis. 
HYPeruricemia, as has been previously mentioned, is frequently 
found in relatives of gout patients. In general, this condition. 
should serve only to alert the physician to the possibility of gout 
in such persons 80 that the proper diagnosis can be made in the case 
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of acute onset of articular distress. There is no actual therapy 
duri..'1g this stC',ge because only a percentage of such persons will 
actually demonstrate clinical gout during their lives. However, the 
physician can recommend the avoidance of obesity, joint trauma, and 
high purine diets for these people. 20 Like~dse, periodic checks 
should probably be made of the uric acid level to keep track of 
any progression of the disease. 
The a.ctual diagnosis of gout is not usually made lh'1til the 
appearance of the first acute episode of joint distress. The diag-
nosis should then be positively made. As mentioned above, a history 
of hyperuricemia makes the diagnosis much easier because the attend-
ing uhysician ~dll be immediately alerted to the diagnosis. At any 
rate this is stage II, the acute attack, and it is here that the 
treatment of gout first begins. Colchicine should be administered 
at the first sign of articular distress in order to ward off the 
severe uain so characteristic of acute gout. Colchicine tablets, 
available in 0.5 mg. (1/120 grain), should be t~~en every hour or 
two until pain is relieved or the toxic symptoms occur. Control of 
the usual attack will require from eight to sixteen tablets. 
Known gout sufferer;:;) should never be far from a supply of colchicine 
tablets because the earlier the medicat/Lon is started during an acute 
attack the quicker relief will be attained. 23 It has been previ-
ously stated that probenecid may precipitate acute attacks during the 
first few months of its administration. It should be pointed out 
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here that if an acute episode of gouty arthritis occurs during 
probenecid therapy, colchicine or phenylbutazone is indicated in 
therapeutic a~ounts, but the probenecid should be continued with-
out change in dosage. 
Stage III, the intercritical periods, .fhich will comprise 
the greatest length of time in the early years of a gout Datient's 
history, should probably receive special ettention. 'The aim of 
therapy during the intercritical periods is to reduce or prevent 
reCl~renccs of acute erticular distress. The best therapy is the 
combination of colchicine with Benemid. Colchicine will relieve 
the acute attack and may be giVen over long periods of time 1tlithout 
the appearance of toxicity or increased tolerance. It has been found 
that patients who helVe been on colchicine for many years will still 
receive a full therapeutic response to this drug during an acute 
episode. Benemid, on the other hand, is effective in lowering the 
uric acid level of the serum and thus viiI I frequently prevent the 
occurrence of acute episodes by bringing the uric acid down to 
normal levels. As much as 2 Gm. of Benemid per day ;,)ay be given 
to severely afflicted persons. It is recommended that a high intake 
of fluids be maintained during a high dosage regimen in order to 
inhibit preciDitation of urates in the renal tubules. Since Bene-
mid Causes an increased excretion of urates, it makes sense to offer 
the kidney a large volume of "rater lnth which to carry away this 
increased volurne of urates. J.n alkaline urine is also considered 
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to be helpful in the prevent~,-on of urate deposition in the kidney. 4 
This can be accomplished by adrr~p2stration of sodium bicarbonate. 
Alkalinization should be continued as long as uricosuric therapy 
is causing an excess production of uric acid in the urine. The 
excess tends to decline as the wiscible pool approaches normal. 
Probenecid is excreted only by glomerular filtration and 
disappears slowly from. the circulation even in the presence of 
impaired renal fUnction. A daily dose of probenecid of 2 Gm. is 
sufficient to sustain, in normal persons, a plasma concentration 
between h and 10 rug./IOO ml. It is possible to chemically evaluate 
the plasma concentration of Benemid, but the PSP test is a sensitive 
indicator of inhibition of renal tubular function by Benemid. If 
the PSP is depressed during Benemid therapy, this indicates that 
the uricosuric and penicillin enhancing effects will also be 
present.~h 
Stage IV, the stage of chronic gouty arthritis, represents the 
end result of long term gouty diseas~. 1bis stage is characterized 
by tbe presence of tophi and low grade aches of the involved joints. 
It is hoped that, it proper management of the disease is exercised 
by the physician, there will not be a progression to this advanced 
stage. F~w~ver, should this stage be reached in the natural 
history of gout it is well to be prepared to treat it. 
'The drugs used for treatment of stage IV are the same as those 
reconnnended for stage III, e.i. colchicine and Benemid. Since acute 
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attacks of joint distress may stiH occur during the chronic 
tophaceous stage it is necessary to maintain the patient on 
colchicine. It should be noted here that the response to treat-
ment of the acute episode may not be as rapid or complete as 
during earlier stages, and several courses of colchicine may be 
necessar:'l to bring such an attack under control.19 It is in the treat-
ment of this chronic stage that Benemid becomes almost indispensable. 
DJ causing an increased excretion of urates this drug Droduces a 
reversal of the flow of urates from subcutaneous and articular areas 
and thus effects a decrease in the size of existL~g tophi and pre-
vents the formation of any new tonhi. The dosage is the amount 
needed to reduce the serQ~ uric acid level to norw~l. If renal 
calculi are present the dosage should be no greater than 0.5 to 
1.0 Gm. per day. Of course a large fluid intake as well as alk-
alinizatior of the urine should be employed as discussed above. 
By following the therapy outlined above for the various stages 
of gout it is possible to keep most gout patients symptom-free while 
not restricting the patient severly in diet or activity. It is 
generally agreed, that temperance should be exercised by the patient 
as far as alcoholic and high purine food intru{e is concerned but 
total abstinence is not necessary_ 
PROGNOSIS 
A paper dealing vdth a disease such as gout would not be 
complete without a discussion of the prognosis. As was stated above, 
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none of the arthritic conditions is curable. Gout, hovrever, is the 
one such condition Iv-hich can be effectively treated and controlled. 
We should repeat here that in order to effectively treat a gouty 
patient it is extremely important that the DPtient cooperate. 
Patients ~mo fail to follow the physician's orders or fail to take 
their medications regularly will, in all probability, continue to 
suffer from the mala~y. However, the prognosis in cooperative 
patients is good in general. This is especially true if the disease 
is diagnosed and treatment instituted early. 
One of the most orrdnous prognostic signs is the formation of 
renal calculi and severe renal disease. It has been previously 
pointed out that renal calculi may be treated effectively by Benemid 
therapy, and that renal function may be improved by the chemical 
removal of such calculi. Hawver, if prirnary renal disease or renal 
vascular disease is present the prognosis is l1mch poorer because 
the effectiveness of the drugs depends upon the kidneys. In general, 
ho~rever, gout is the most gratifying of the arthritides to treat, 
and the prognosis is to be considered quite good from the stan.d-
point of control of ~~otoms and chronic manifestations of the 
disease. 
SUl'1fIARY 
On the preceding pages 1<Je have endeavored to present a concise 
but complete picture of gout. Gout is a disease "Thich has plagued 
man for centuries, being mentioned in eprly writings including the 
-26-
Bible. Unlike other arthritic conditions, gout is treatable. It 
is nO\,-I genarally accepted that anyone \'-Jho suffers from gout does 
so needlessly. Herein lies the responsibility of the physician, 
e.i., to make an honest effort to rule out a diagnosis of gout before 
allowing a patient to suffer with this condition thinking it is 
a nontreatable form of arthritis. 
Gout is IGlown to be an heredit~~ disease, and its incidence 
is obviously sex-linked since it attacks males in a ratio of 
95.5/4.5 over females. It is also included among the "inborn 
errors of metabolism" and is linked to purine metabolism and 
uric acid concentrations in the serum. Recent studies using iso-
topically labeled uric acid have confirmed and clarified much of 
the etiology of gout. 
The clinical aspects of gout .uth its severe joint distress 
are included in detail in the preceding pages. Gout should be 
considered in the differential diagnosiS of any acute inflamIl1atory 
joint. 
The currently accepted cOIrrbined therapy using both colchicine 
and probenecid is described in some detail, as well as the pharm-
acologic background and adion of these drugs. Although other 
drugs may be useful in treatment of gout it is felt th.2~t the 
above drugs provide the best advantage for continued long-term 
therapy. 
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ADDENDID1 
,since the completion of this manuscript, certain articles 
have come to my attention which appear to shed new light upon 
the possible mechanism of action of colchicine in the treatment 
of gout. 
Seegmiller and Howell, in an article published in June of 
1962, proposed that colchicine diminished the metabolic activity 
of the leukocyte Which causes decreased phagocytosis and lactic 
acid production. They hypothesized that this would interl~pt the 
cycle of rapid crystal deposit, inflammatorJ response and phagocyt-
osis of those crystals which is characteristic of acute gout. These 
two investigators were able to demonstrate an in vivo as 1"ell as 
an in vitro effect of colchicine at therapeutic levels. They pre-
treated gouty volunteers with therapeutic doses of colchicine and 
found that the inflammatory response to the injection of s9dium 
urate crystals was substantially reduced. They demonstrated the 
decreased pha~ocytosis effect of colchicine in an in vitro system 
using urate crystals and human leukocytes. Since phagocytosis 
increases lactic acid production by granulocytes, they reasoned 
that a decrease in phagocytosis might sufficiently reduce the local 
lactic acid production to interrupt the cycle mentioned above. 31,32 
Snodell published a student thesis in August of 1962 ~mich 
suggests that colchicine may have some effect upon the metabolism 
of purines. He found that the rat intestine is eble to convert 
various purine compounds to uric acid under in vitro conditions. 
He observed that colchicine stimulated the oxidation of hypoxanthine 
to uric acid by the rat intestine. Colchicine appeared to inhibit 
the conversion of inosine, the riboside of hypoxanthine, to uric 
acid. He offered no explanation of these findings but suggested 
that lI colchicine may exhibit its therapeutic properties in gout by 
altering some phase (s) of purine metabolism,,}3 
Thus w'"e see that there is evidence to support at least two 
possible mechanisms of action of colchicine in gout. hhile either 
of these possibilities seems plausible as an explanation of the 
action of colchicine, the fact that there are two such possibilities 
only serves to emphasize the fact that in all probability the final 
word on the mechanism of action of colchicine in gout has not been 
written. This topic certainly remains open for further investig-
ation. While many of the actions of colchicine are known, its 
action in gout remains today mostly within the realm of hypothesis. 
CotJCLUSIONS 
A.cute joint distress m8y be the primary manifesta,tion of a 
number of diseases which we usually place in the general category 
of arthri tic conditions. Undoubtedly some of the so-called anth-
ritis sufferers are actually enduring needless pain and discomfort of 
treatable gouty arthritis rather than one of the untreatable forms. 
This is needless suffering because i'rl.th proper diagnosis and care-
ful managexnent almost untold relief could be afforded these :oeople. 
It is the responsibility of the physician to recognize these persons 
and possibly prevent their suffering from gouty arthritis. I believe 
that the greatest fault of physicians is their failure to think of 
gout e,s a possibility in cases of 2.cute joint distress. Yet the 
diagnosis of gout; once it is thought of; is not difficult. Any male 
patient vii th articular distress l.;ho :.8 in the middle age group 
should be considered a prL'Tle candidate for gout, especially in the 
presence of a family history of gout. 
The serum uric acid level may virtuC'~ly cinch the diagnOSis 
of gout; hOi'Jever, this test is not particularly easy to perform 
and a reliable laboratory should be consulted for this determination. 
It should be remembered that uric acid level may not accurately 
reflect the severity of the clinical manifestations. Some persons 
may show syrr~toms of gout at relatively low uric acid concentrations 
while others may be symptom free at much higher uric acid levels. 
In general, however, no attempt to diagnose the condition should be 
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made until e.fter the occurence of the first acute attack of joint 
distress. Since gout is hereditary and thus a familial disease, 
all close male relatives of gout sufferers should have uric acid 
determinations to discover nonsyrnptomatic hJrperuricemias. Any 
such relative who is found to have a hyperuricemia in the absence of 
symptoms should be ir...formed of this fact and its implications. He 
should also be noted by the physician as a potential gout pa.tient 
so that when articular s;:rmptoms do develop the correct diagnosis 
may be made and treatn'lent instituted early. 
H.any' of'the ideas'previously held by'physicians concerning 
gout have been dispelled by closer evaluation arrl recent studies. 
For ex~~le, it has long been thought that gout was a disease 
acquired mainly by Europeans from overindulgence in food or drink. 
~~ now know that gout is an hereditarJ condition, and is very 
little, if any, affected by diet. Since uric acid is a product of 
purine metabolism, it is advisable for severe gout sufferers to 
abstain only from those foods 'tihich are high in purines. 
The essential thing to remember is that the diagnosis of this 
disease is the responsibility of every physician who practices 
general medicine and treats arthritic conditions. Since gout is 
the only one of these painful conditions which can be effectively 
treated and relieved the physician should m2~e special effort to 
determine ",nether any of hiE arthritic cases could possibly have 
been originally misdiagnosed, and whether one of his ltarthritisll 
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patients may, in fact, be suffering from the treatable condition 
of gout. I believe that physicians should periodically review their 
cases of arthritis patients to seek out possible gout sufferers, and 
to attempt relief of their suffering. Serum uric acid determinations 
should be a principal part of the work-up of every case involving 
articular distress. Likewise, as has been previously mentioned, 
relatives of gout patients shou1d be cardfully screened as possible 
future gout patients. This is especially true of males. 'Ihe most 
important aspect in the diagnosis of gout remains, however, merely 
to thi~~ of it as a possibility. 
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